COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM

被引：0
|
作者：
Holanda, P. [1 ]
Salgado De Santana, C. [2 ]
Senna, T. [1 ]
Carmo, L. [1 ]
Alexandre, R. F. [1 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer Inc, Santos, SP, Brazil
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI11
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
    Ferreira, P.
    Senna, T.
    Sebastiao, M.
    Alexandre, R. F.
    Almeida, P.
    VALUE IN HEALTH, 2023, 26 (06) : S68 - S69
  • [32] Tofacitinib for the Treatment of Ulcerative Colitis: An Updated Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program
    Winthrop, Kevin L.
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Hart, Ailsa
    Alharbi, Othman R.
    Salese, Leonardo
    Lawendy, Nervin
    Mundayat, Rajiv
    Su, Chinyu
    Reinisch, Walter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S323 - S323
  • [33] Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
    Perin, Ramir Luan
    Magro, Daniela Oliveira
    Andrade, Adriana Ribas
    Argollo, Marjorie
    Carvalho, Nayara Salgado
    Damiao, Aderson Omar Moura Cintra
    Dotti, Adriana Zanoni
    Ferreira, Sandro da Costa
    Flores, Cristina
    Ludvig, Juliano Coelho
    Nones, Rodrigo Bremer
    Queiroz, Natalia Sousa Freitas
    Parra, Rogerio Serafim
    Steinwurz, Flavio
    Teixeira, Fabio Vieira
    Kotze, Paulo Gustavo
    CROHNS & COLITIS 360, 2023, 5 (01)
  • [34] Cost-Effectiveness Analysis and Budget Impact: Antimuscarinics and Mirabegron for the Treatment of Patients With Urge Urinary Incontinence: The Brazilian Public Health System Perspective
    Zanghelini, Fernando
    de Oliveira Jr, Haliton Alves
    Castano Silva, Thales Brendon
    Pereira, Daniel da Silva
    Araujo de Oliveira, Gustavo Laine
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 85 - 92
  • [35] COMPARISON OF ULCERATIVE COLITIS SURVEILLANCE STRATEGIES. AN ANALYSIS OF COST-EFFECTIVENESS
    Landy, J.
    Ignjatovic, A.
    Thomas-Gibson, S.
    Hart, A.
    Saunders, B.
    GUT, 2011, 60
  • [36] Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
    Parra, Rogerio S.
    Froes, Renata de Sa Brito
    Magro, Daniela Oliveira
    Ferreira, Sandro da Costa
    de Mello, Munique Kurtz
    de Azevedo, Matheus Freitas Cardoso
    Damiao, Aderson Omar Mourao Cintra
    Carlos, Alexandre de Sousa
    Barros, Luisa Leite
    de Miranda, Maria Luiza Queiroz
    Vieira, Andrea
    Moraes Sales, Marcos Paulo
    Gabot, Gilmara
    Cassol, Ornella Sari
    Alves Junior, Antonio Jose Tiburcio
    Lubini, Marcio
    Machado, Marta Brenner
    Flores, Cristina
    Teixeira, Fabio Vieira
    Coy, Claudio Saddy Rodrigues
    Sassaki, Ligia Yukie
    Feres, Omar
    Chebli, Julio Maria Fonseca
    Zaltman, Cyrla
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S) : S25 - S25
  • [37] COST PER RESPONDER ANALYSIS OF BIOLOGIC TREATMENTS FOR ULCERATIVE COLITIS IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Souza, P. V. S.
    Baida, R.
    Gomes, T. N. F.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [38] Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naive Patients with Moderate-to-Severe Ulcerative Colitis in Japan
    Kobayashi, Taku
    Hoshi, Masato
    Yuasa, Akira
    Arai, Shoko
    Ikeda, Mitsunobu
    Matsuda, Hiroyuki
    Kim, Seok-Won
    Hibi, Toshifumi
    PHARMACOECONOMICS, 2023, 41 (05) : 589 - 604
  • [39] A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
    Ewa Stawowczyk
    Paweł Kawalec
    PharmacoEconomics, 2018, 36 : 419 - 434
  • [40] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
    Rosim, M. P.
    Riveros, B. S.
    Kim, H. S.
    Nakada, C.
    Freire, W. R.
    VALUE IN HEALTH, 2018, 21 : S426 - S426
12345